UPPSALA, Sweden — Swedish technology firm Q-linea hopes to deliver to market within the next three years a clinical assay that can identify bacteria responsible for sepsis and determine its susceptibility to antibiotics.

CEO Jonas Jarvius said that the privately held company is "putting all of its focus" on the diagnostics market, looking to parlay its nucleic acid- and protein-detection capabilities into a steady revenue stream from hospitals that would use the test to select the most effective antibiotics regimens for patients.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.